Dimension Therapeutics, Inc. (DMTX) Upgraded to “Neutral” by Citigroup Inc.
Citigroup Inc. upgraded shares of Dimension Therapeutics, Inc. (NASDAQ:DMTX) from a sell rating to a neutral rating in a research report sent to investors on Tuesday morning. They currently have $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.50.
Several other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Dimension Therapeutics from a hold rating to a sell rating in a report on Monday, July 10th. Canaccord Genuity lowered their price target on shares of Dimension Therapeutics from $20.00 to $12.00 and set a buy rating on the stock in a research note on Wednesday, June 28th. Cantor Fitzgerald set a $3.00 price target on shares of Dimension Therapeutics and gave the company a hold rating in a research note on Saturday, June 10th. ValuEngine raised shares of Dimension Therapeutics from a strong sell rating to a sell rating in a research report on Saturday. Finally, Chardan Capital reissued a hold rating on shares of Dimension Therapeutics in a research report on Monday, August 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $4.53.
Shares of Dimension Therapeutics (NASDAQ:DMTX) traded up 0.420% on Tuesday, hitting $5.975. 170,491 shares of the stock traded hands. The firm’s 50 day moving average is $3.86 and its 200 day moving average is $2.02. The firm’s market capitalization is $149.69 million. Dimension Therapeutics has a 52 week low of $1.05 and a 52 week high of $8.00.
Dimension Therapeutics (NASDAQ:DMTX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.49). Dimension Therapeutics had a negative net margin of 358.21% and a negative return on equity of 98.72%. The company had revenue of $4.37 million for the quarter. On average, analysts expect that Dimension Therapeutics will post ($2.10) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/04/dimension-therapeutics-inc-dmtx-upgraded-to-neutral-by-citigroup-inc.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC bought a new position in shares of Dimension Therapeutics in the first quarter valued at $108,000. Goldman Sachs Group Inc. increased its holdings in Dimension Therapeutics by 206.7% during the second quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock worth $117,000 after buying an additional 54,231 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC increased its holdings in Dimension Therapeutics by 6.7% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 390,403 shares of the biotechnology company’s stock worth $683,000 after buying an additional 24,489 shares during the last quarter. 70.75% of the stock is owned by institutional investors.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Stock Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related stocks with our FREE daily email newsletter.